Table 2 Treatment modality received by Aboriginality, demographic and clinical variables
| Â | Hospitalised with primary diagnosis of cancer | Received surgery | Received systemic therapy | Received radiotherapy | Received each of surgery, systemic and radiotherapy | Reveived no surgery, systemic or radiotherapy | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aboriginal cohort | Matched non-Indigenous cohort | p | Aboriginal cohort | Matched non-Indigenous cohort | p | Aboriginal cohort | Matched non-Indigenous cohort | p | Aboriginal cohort | Matched non-Indigenous cohort | p | Aboriginal cohort | Matched non-Indigenous cohort | p | Aboriginal cohort | Matched non-Indigenous cohort | p | |
Total | ||||||||||||||||||
 n | 617 | 649 |  | 408 | 488 |  | 252 | 334 |  | 309 | 360 |  | 77 | 140 |  | 183 | 110 |  |
 column % | 100.0% | 100.0% |  | 100.0% | 100.0% |  | 100.0% | 100.0% |  | 100.0% | 100.0% |  | 100.0% | 100.0% |  | 100.0% | 100.0% |  |
Age | ||||||||||||||||||
 <50 years | 28.5% | 25.0% | 0.17 | 32.8% | 26.0% | 0.07 | 31.0% | 27.2% | 0.96 | 29.4% | 25.6% | 0.50 | 35.1% | 26.4% | 0.38 | 19.7% | 18.2% | 0.23 |
 50-69 years | 53.2% | 53.2% |  | 52.2% | 55.9% |  | 53.6% | 58.7% |  | 54.0% | 56.1% |  | 54.5% | 60.0% |  | 46.4% | 38.2% |  |
 70+ years | 18.3% | 21.9% |  | 15.0% | 18.0% |  | 15.5% | 14.1% |  | 16.5% | 18.3% |  | 10.4% | 13.6% |  | 33.9% | 43.6% |  |
Sex | ||||||||||||||||||
 Male | 47.2% | 48.1% | 0.72 | 42.6% | 45.7% | 0.36 | 44.8% | 48.5% | 0.38 | 52.1% | 49.7% | 0.54 | 45.5% | 42.1% | 0.64 | 54.6% | 48.2% | 0.28 |
 Female | 52.8% | 51.9% |  | 57.4% | 54.3% |  | 55.2% | 51.5% |  | 47.9% | 50.3% |  | 54.5% | 57.9% |  | 45.4% | 51.8% |  |
Primary site | ||||||||||||||||||
 Colorectal (C18-C21) | 11.2% | 11.1% | 0.92 | 13.2% | 13.3% | 0.55 | 12.7% | 10.8% | 0.86 | 7.4% | 6.4% | 0.66 | 15.6% | 8.6% | 0.31 | 8.2% | 6.4% | 0.39 |
 Lung (C33-C34) | 13.9% | 13.9% |  | 5.4% | 7.8% |  | 12.7% | 12.6% |  | 19.1% | 20.3% |  | 3.9% | 10.0% |  | 14.2% | 12.7% |  |
 Breast (C50 & Female) | 10.0% | 10.9% |  | 13.7% | 13.9% |  | 18.3% | 17.4% |  | 13.3% | 14.2% |  | 32.5% | 30.0% |  | 4.9% | 3.6% |  |
 Cervix (C53) | 3.1% | 2.3% |  | 4.2% | 2.9% |  | 1.2% | 2.1% |  | 4.9% | 2.8% |  | 1.3% | 1.4% |  | 1.1% | 4.5% |  |
 All others | 61.8% | 61.8% |  | 63.5% | 62.1% |  | 55.2% | 57.2% |  | 55.3% | 56.4% |  | 46.8% | 50.0% |  | 71.6% | 72.7% |  |
Geographically remote | ||||||||||||||||||
 No | 76.7% | 95.5% | <0.01 | 78.4% | 95.7% | <0.01 | 86.1% | 94.3% | <0.01 | 80.9% | 94.4% | <0.01 | 80.5% | 95.7% | <0.01 | 68.9% | 98.2% | <0.01 |
 Yes | 23.3% | 4.5% |  | 21.6% | 4.3% |  | 13.9% | 5.7% |  | 19.1% | 5.6% |  | 19.5% | 4.3% |  | 31.1% | 1.8% |  |
Comorbid conditions (Elixhauser) | ||||||||||||||||||
 0-3 | 84.3% | 95.2% | <0.01 | 85.8% | 96.9% | <0.01 | 88.9% | 96.4% | <0.01 | 88.7% | 96.1% | <0.01 | 94.8% | 97.1% | 0.38 | 86.3% | 91.8% |  |
 4+ | 15.7% | 4.8% |  | 14.2% | 3.1% |  | 11.1% | 3.6% |  | 11.3% | 3.9% |  | 5.2% | 2.9% |  | 13.7% | 8.2% |  |
Summary stage at diagnosis | ||||||||||||||||||
 Localised | 34.2% | 49.8% | <0.01 | 40.0% | 55.7% | <0.01 | 32.9% | 43.1% | 0.04 | 40.5% | 46.7% | 0.25 | 36.4% | 45.7% | 0.39 | 29.0% | 46.4% | 0.01 |
 Regional | 21.9% | 18.6% |  | 26.0% | 20.1% |  | 24.2% | 20.7% |  | 24.3% | 22.8% |  | 29.9% | 27.1% |  | 12.0% | 9.1% |  |
 Distant/Unstageable | 43.9% | 31.6% |  | 34.1% | 24.2% |  | 42.9% | 36.2% |  | 35.3% | 30.6% |  | 33.8% | 27.1% |  | 59.0% | 44.5% |  |
Vital statusb | ||||||||||||||||||
 Alive | 29.0% | 45.6% | <0.01 | 38.0% | 55.9% | <0.01 | 35.7% | 44.9% | 0.08 | 29.4% | 41.1% | <0.01 | 40.3% | 48.6% | 0.50 | 12.0% | 26.4% | <0.01 |
 Cancer death | 60.0% | 45.0% |  | 48.3% | 35.2% |  | 57.5% | 49.4% |  | 62.1% | 52.5% |  | 55.8% | 47.9% |  | 73.8% | 48.2% |  |
 Non-cancer death | 11.0% | 9.4% |  | 13.7% | 8.8% |  | 6.7% | 5.7% |  | 8.4% | 6.4% |  | 3.9% | 3.6% |  | 14.2% | 25.5% |  |